It also notes the importance of working all the major muscle groups: legs, hips, back, abdomen, chest, shoulders, and arms
Shin YJ, Yang JW, Jeong H, et al
The SURPASS-CVOT trial is a phase 3, randomized, double-blind cardiovascular outcomes trial that will assess tirzepatide for both non-inferiority and superiority against dulaglutide. For dulaglutide, this effect is already proven: According to the Trulicity website, the drug may be used in adults with type 2 diabetes to reduce the risk of major cardiovascular events (problems having to do with the heart and blood vessels) such as death, heart attack, or stroke in people who have heart disease or multiple cardiovascular risk factors. How do I know which medication is right for me
By the end of the study period, 48% of participants exhibited HbA1c levels of less than 7%